Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2200

Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor

$
0
0
Plus, news about Maat Pharma, Secretome Therapeutics, 35Pharma, Medigene and Doron Therapeutics: Aviceda Therapeutics’ $200M financing: The Boston-area biotech is looking to raise a $200 million equity round, according to an SEC

Viewing all articles
Browse latest Browse all 2200

Trending Articles